With Increasing New Drug INDs Projected, How Much More Workload Can US FDA Handle?

 
• By Derrick Gingery
  
workload
While INDs are expected to increase in CDER and CBER, fewer efficacy and manufacturing supplements are expected to be submitted. • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards